Journal of Bone Oncology最新文献

{"title":"Analysis of skeletal pain, general symptoms and patient-reported outcome measures and their value in detecting symptomatic progression – An interdisciplinary prospective study in patients with multiple myeloma","authors":"Carlotta Pietsch ,&nbsp;Monika Engelhardt ,&nbsp;Gabriele Ihorst ,&nbsp;Laura Wystrach ,&nbsp;Johannes Jung ,&nbsp;Hagen Schmal ,&nbsp;Andreas Frodl ,&nbsp;Ralph Wäsch ,&nbsp;Evangelos Terpos ,&nbsp;Georg W. Herget","doi":"10.1016/j.jbo.2025.100685","DOIUrl":"10.1016/j.jbo.2025.100685","url":null,"abstract":"<div><div>Delayed diagnosis of multiple myeloma (MM) and progressive disease (PD) can both increase the risk of skeletal complications and do affects patients’ quality of life (QoL). In this prospective study we analyzed skeletal pain, general symptoms and patient-reported outcome measures (PROMs) in patients with MM and their value in detecting symptomatic progression.</div><div>We evaluated 502 patients, 47 with initial diagnosis (ID) of MM and 455 follow-up patients. At ID, 74% reported bone pain, mostly in the spine. General symptoms, particularly fatigue, were present in 89% of the patients. 88/455 (19%) of the follow-up patients experienced PD. Of these, 65% reported skeletal pain and 81% exhibited general symptoms, with fatigue being the most common. PD was suspected and confirmed as the cause of clinical symptoms in 59/88 (67%) and not suspected in 29/88 (33%). Occurrence and character of bone pain and general symptoms differed significantly between patients with and without PD, as did QoL and health-related status. Logistic regression analysis demonstrated that bone pain at night, pain in various locations, pain of known character with occurrence in different location, pain in the chest, pelvis, and thigh as well as fatigue and weight loss were associated with an increased risk of PD.</div><div>In conclusion, bone pain and general symptoms are helpful in identifying both MM and PD. PROMs can aid in the diagnosis of PD through symptom-based patient assessment. Serologic and, especially in the case of skeletal complaints, additional radiologic diagnostics are required to confirm suspected and to detect unexpected PD.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100685"},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma","authors":"Guannan Bai ,&nbsp;Shaobo Zhao ,&nbsp;Manli Zhao ,&nbsp;Limiao Chen ,&nbsp;Wenhao Chen","doi":"10.1016/j.jbo.2025.100684","DOIUrl":"10.1016/j.jbo.2025.100684","url":null,"abstract":"<div><div>Osteosarcoma is the most common bone malignancy in children and adolescents. Patients with metastatic and recurrent osteosarcoma have poor prognosis. Regorafenib is a multi-kinase inhibitor recommended as a complement to standard chemotherapy in the treatment of advanced osteosarcoma. The mechanisms associated with regorafenib resistance remains unclear.</div><div>In this study we performed transcriptomics, proteomics and phosphorylated proteomics using regorafenib-treated osteosarcoma cell lines (MG-63, HOS-MNNG for transcriptomics, HOS-MNNG for proteomics and phosphorylated proteomics). After comprehensive multiomics and verification analyses of differentially expressed genes, essential genes for the malignancy of osteosarcoma cells were identified. The effects of essential genes on the proliferation, invasion, and migration of osteosarcoma were determined. The study also evaluated their role in the apoptosis of osteosarcoma cells. The up-regulation of essential genes was determined by immunohistochemistry assays.</div><div>Using comprehensive multiomics and verification analyses we found that the CTDSPL2 gene might play a role in the malignancy and Regorafenib resistance in osteosarcoma. In vitro and clinical specimen assays demonstrated that CTDSPL2 promotes the proliferation, invasion and metastasis of osteosarcoma cells, while inhibiting tumor cell apoptosis.</div><div>In conclusion CTDSPL2 was identified as an essential gene for survival of osteosarcoma cells. Knockdown of CTDSPL2 expression significantly inhibited the proliferation, invasion, and metastasis of osteosarcoma cells, suggesting that it is involved in the formation and development of osteosarcoma tumors. Our data showed that CTDSPL2 is a potential therapeutic target for patients with osteosarcoma.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100684"},"PeriodicalIF":3.4,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a nomogram for prognosis of bone metastatic disease in patients with esophageal squamous cell carcinoma: A retrospective study in the SEER database and China cohort","authors":"Bo Huang ,&nbsp;Wei-Dong Wang ,&nbsp;Fang-Cai Wu ,&nbsp;Xiao-Mei Wang ,&nbsp;Bu-Qing Shao ,&nbsp;Ying-Miao Lin ,&nbsp;Guo-Xing Zheng ,&nbsp;Gui-Qiang Li ,&nbsp;Can-Tong Liu ,&nbsp;Yi-Wei Xu ,&nbsp;Xin-Jia Wang","doi":"10.1016/j.jbo.2025.100683","DOIUrl":"10.1016/j.jbo.2025.100683","url":null,"abstract":"<div><h3>Purpose</h3><div>Esophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor worldwide, and individuals with ESCC and bone metastasis (BM) often face a challenging prognosis. Our objective was to identify the risk and prognostic factors associated with BM in patients with ESCC and develop a nomogram for predicting Cancer-Specific Survival (CSS) which following the occurrence of BM.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of data pertaining to ESCC patients with BM registered in the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015, as well as those treated at a Chinese institution from 2006 to 2020. Significant prognostic factors for CSS were assessed through univariate and multivariate Cox regression analyses. Subsequently, a nomogram was developed utilizing the SEER database and externally validated using real-world evidence from a Chinese cohort.</div></div><div><h3>Results</h3><div>A total of 266 patients from the SEER database and 168 patients from the Chinese cohort were included in the analysis. In the SEER cohort, multivariate analysis indicated that chemotherapy, radiotherapy, liver metastasis, brain metastasis, and sex were independent prognostic factors for ESCC with BM. The prognostic nomogram demonstrated areas under the ROC curve (AUCs) of 0.823, 0.796, and 0.800, respectively, for predicting 3-, 6-, and 12-month CSS. In the Chinese validation cohort, the nomogram exhibited acceptable discrimination (AUCs: 0.822, 0.763, and 0.727) and calibration ability.</div></div><div><h3>Conclusion</h3><div>The study developed a prognostic nomogram to predict CSS in ESCC patients with BM, which can help clinicians assess survival and make individualized treatment decisions.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100683"},"PeriodicalIF":3.4,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in bone Metastases: A systematic review in guideline adherence of 92 studies","authors":"Lotte R. van der Linden ,&nbsp;Ioannis Vavliakis ,&nbsp;Tom M. de Groot ,&nbsp;Paul C. Jutte ,&nbsp;Job N. Doornberg ,&nbsp;Santiago A. Lozano-Calderon ,&nbsp;Olivier Q. Groot","doi":"10.1016/j.jbo.2025.100682","DOIUrl":"10.1016/j.jbo.2025.100682","url":null,"abstract":"<div><h3>Background</h3><div>The last decade has witnessed a surge in artificial intelligence (AI). With bone metastases becoming more prevalent, there is an increasing call for personalized treatment options, a domain where AI can greatly contribute. However, integrating AI into clinical settings has proven to be difficult. Therefore, we aimed to provide an overview of AI modalities for treating bone metastases and recommend implementation-worthy models based on TRIPOD, CLAIM, and UPM scores.</div></div><div><h3>Methods</h3><div>This systematic review included 92 studies on AI models in bone metastases between 2008 and 2024. Using three assessment tools we provided a reliable foundation for recommending AI modalities fit for clinical use (TRIPOD or CLAIM ≥ 70 % and UPM score ≥ 10).</div></div><div><h3>Results</h3><div>Most models focused on survival prediction (44/92;48%), followed by imaging studies (37/92;40%). Median TRIPOD completeness was 70% (IQR 64–81%), CLAIM completeness was 57% (IQR 48–67%), and UPM score was 7 (IQR 5–9). In total, 10% (9/92) AI modalities were deemed fit for clinical use.</div></div><div><h3>Conclusion</h3><div>Transparent reporting, utilizing the aforementioned three evaluation tools, is essential for effectively integrating AI models into clinical practice, as currently, only 10% of AI models for bone metastases are deemed fit for clinical use. Such transparency ensures that both patients and clinicians can benefit from clinically useful AI models, potentially enhancing AI-driven personalized cancer treatment.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100682"},"PeriodicalIF":3.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting lung cancer bone metastasis using CT and pathological imaging with a Swin Transformer model","authors":"Wanling Li ,&nbsp;Xin Zou ,&nbsp;Jie Zhang ,&nbsp;Minghong Hu ,&nbsp;Guanfeng Chen ,&nbsp;Shanshan Su","doi":"10.1016/j.jbo.2025.100681","DOIUrl":"10.1016/j.jbo.2025.100681","url":null,"abstract":"<div><div>Bone metastasis is a common and serious complication in lung cancer patients, leading to severe pain, pathological fractures, and reduced quality of life. Early prediction of bone metastasis can enable timely interventions and improve patient outcomes. In this study, we developed a multimodal Swin Transformer-based deep learning model for predicting bone metastasis risk in lung cancer patients by integrating CT imaging and pathological data. A total of 215 patients with confirmed lung cancer diagnoses, including those with and without bone metastasis, were included. The model was designed to process high-resolution CT images and digitized histopathological images, with the features extracted independently by two Swin Transformer networks. These features were then fused using decision-level fusion techniques to improve classification accuracy. The Swin-Dual Fusion Model achieved superior performance compared to single-modality models and conventional architectures such as ResNet50, with an AUC of 0.966 on the test data and 0.967 on the training data. This integrated model demonstrated high accuracy, sensitivity, and specificity, making it a promising tool for clinical application in predicting bone metastasis risk. The study emphasizes the potential of transformer-based models to revolutionize bone oncology through advanced multimodal analysis and early prediction of metastasis, ultimately improving patient care and treatment outcomes.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100681"},"PeriodicalIF":3.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of preoperative hematocrit and platelet count with morbidity after pathologic fracture fixation","authors":"Mohyeddine El Sayed ,&nbsp;Ryley Zastrow ,&nbsp;Sassine Youssef ,&nbsp;Adam S. Levin","doi":"10.1016/j.jbo.2025.100679","DOIUrl":"10.1016/j.jbo.2025.100679","url":null,"abstract":"<div><h3>Background</h3><div>Anemia and abnormal platelet count are common among patients with cancer and are associated with complications after orthopaedic procedures. We studied associations between these conditions and morbidity within 30 days after surgery for pathologic femur or humerus fracture.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed data from the National Surgery Quality Improvement Project database for 145,030 adults following surgical fixation of a pathologic femur or humerus fracture from 2010 to 2020. Multivariable logistic regressions compared 30-day complications between patients with mild or severe anemia versus those with normal hematocrit and between patients with thrombocytopenia or thrombocytosis versus those with normal platelet count.</div></div><div><h3>Results</h3><div>Likelihood of extended hospitalization (≥6 days) was higher in patients with mild anemia (odds ratio [OR]: 1.47; 95 % confidence interval [CI]: 1.44, 1.51) and severe anemia (OR: 2.14; 95 % CI: 2.06, 2.23). Likelihood of all-cause morbidity was also higher among those with mild anemia (OR: 1.17; 95 % CI: 1.13, 1.21) and severe anemia (OR: 1.35; 95 % CI: 1.28, 1.42). Similarly, likelihood of extended hospitalization was higher in patients with thrombocytopenia (OR: 1.25; 95 % CI: 1.22, 1.29) and thrombocytosis (OR: 1.24; 95 % CI: 1.13, 1.36). Likelihood of all-cause morbidity was also higher for those with thrombocytopenia (OR: 1.12; 95 % CI: 1.07, 1.16) and thrombocytosis (OR: 1.21; 95 % CI: 1.07, 1.37).</div></div><div><h3>Conclusion</h3><div>Preoperative anemia and platelet abnormalities were potentially modifiable risk factors associated with postoperative complications following surgery for pathologic fracture.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100679"},"PeriodicalIF":3.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of myeloma bone disease: When, how often, and for how long?","authors":"Michael Tveden Gundesen ,&nbsp;Fredrik Schjesvold ,&nbsp;Thomas Lund","doi":"10.1016/j.jbo.2025.100680","DOIUrl":"10.1016/j.jbo.2025.100680","url":null,"abstract":"<div><div>The landscape of MM has changed dramatically in recent years. Several new and more effective treatments have been introduced that not only makes patients live longer but also brings them into a deeper remission. This makes the potential total exposure of bone protective treatment much higher but perhaps also less needed. New and more precise imagining techniques have been introduced making detection of bone disease more sensitive, and the introduction of SLiM-CRAB criteria have changed the parameters used in old clinical trials investigating treatment of MM bone disease. New data have also emerged investigating the effect of the RANKL inhibitor denosumab compared to zoledronic acid (ZOL). Randomized trials have investigated longer treatment durations, which becomes more relevant as patients now live longer.</div><div>In addition in this review, data regarding interval between individual treatment, impact of remission status, new data in relation to rebound after discontinuation and of denosumab, as well as the rational for drug holidays before dental procedures will also be discussed.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100680"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143777626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding the immune landscape in Ewing sarcoma pathogenesis: The role of tumor infiltrating immune cells and immune milieu","authors":"Rajiv Ranjan Kumar ,&nbsp;Nikita Agarwal ,&nbsp;Akshi Shree ,&nbsp;Jaya Kanta Gorain ,&nbsp;Ekta Rahul ,&nbsp;Shuvadeep Ganguly ,&nbsp;Sameer Bakhshi ,&nbsp;Uttam Sharma","doi":"10.1016/j.jbo.2025.100678","DOIUrl":"10.1016/j.jbo.2025.100678","url":null,"abstract":"<div><div>Ewing sarcoma (EwS) is the second most prevalent pediatric bone malignancy, characterized by its aggressive behavior and unfavorable prognosis. The tumor microenvironment (TME) of EwS is shaped by immunosuppressive components, including myeloid-derived suppressor cells, tumor-associated macrophages, and immune checkpoint molecules such as PD-1/PD-L1 and HLA-G. These elements impair anti-tumor immune responses by modulating the function of tumor-infiltrating immune cells, such as regulatory T cells (Tregs), CD8⁺ T cells, and natural killer cells. Chemokines, including CXCL9 and CXCL12, and cytokines, such as transforming growth factor-beta and interleukin-10, further contribute to immune suppression and promote metastatic dissemination. Recent advances in immunotherapy have highlighted the therapeutic potential of modulating immune cells and signaling pathways to enhance anti-tumor immunity. This review provides a comprehensive analysis of the complex immune landscape within the EwS TME, focusing on the mechanistic roles of key immune components and their potential as therapeutic targets. Understanding these interactions could pave the way for innovative treatment strategies to improve clinical outcomes in patients with EwS.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100678"},"PeriodicalIF":3.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone cement implantation syndrome in patients with cemented endoprostheses for metastatic bone disease in the femur","authors":"Thea Hovgaard Ladegaard ,&nbsp;Jakob Stensballe ,&nbsp;Michael Mørk Petersen ,&nbsp;Michala Skovlund Sørensen","doi":"10.1016/j.jbo.2025.100677","DOIUrl":"10.1016/j.jbo.2025.100677","url":null,"abstract":"<div><h3>Background</h3><div>Patients with bone metastases in the femur (BMf) may experience pathological fractures requiring surgery with cemented endoprostheses (EPR). At cementation and prosthesis insertion, patients are at risk of experiencing hypoxia, hypotension, cardiac failure and potentially death, known as bone cement implantation syndrome (BCIS). We aimed to 1) investigate the incidence and grade of BCIS in patients with BMf treated with cemented EPR, and 2) examine if the incidence or extent of BCIS has decreased after a change of a combined anesthesiologic and surgical protocol.</div></div><div><h3>Methods</h3><div>We retrospectively assessed patients with BMf operated with cemented EPR in two periods 2017 – 2018 (early cohort) and 2019 – 2020 (late cohort) and stratified before and after the intervention.</div></div><div><h3>Results</h3><div>Comparing the early and late cohorts, 26/86 (32 %) vs. 30/80 (35 %) experienced BCIS, but mild BCIS (grade 0 + 1) was seen in 79 % vs. 86 %, and severe BCIS (grade 2 + 3) in 21 % vs. 14 %. In the late cohort the per-operative use of vasopressors was higher (86 % vs. 59 %, p &lt; 0.001), we found fewer pulmonary embolisms (PE) (p = 0.024), and a trend toward a reduced length of stay (LOS). 30-day survival was lower for patients with grade 0 + 1 compared to grade 2 + 3 (p = 0.03).</div></div><div><h3>Conclusions</h3><div>BCIS occurs in more than 1/3 of patients operated for BMf with cemented EPR. An increased multidisciplinary focus on BCIS may reduce the complications of BCIS, such as PE and LOS.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100677"},"PeriodicalIF":3.4,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical management of spinal metastases: A cross-continental study in the United States and the Netherlands","authors":"Jantijn J.G.J. Amelink ,&nbsp;Bram T. van Munster ,&nbsp;Bas J.J. Bindels ,&nbsp;Robertus J.B. Pierik ,&nbsp;Jasper van Tiel ,&nbsp;Olivier Q. Groot ,&nbsp;Nicolien Kasperts ,&nbsp;Daniel G. Tobert ,&nbsp;Jorrit-Jan Verlaan","doi":"10.1016/j.jbo.2025.100676","DOIUrl":"10.1016/j.jbo.2025.100676","url":null,"abstract":"<div><h3>Background</h3><div>There is currently no consensus on the optimal surgical treatment for patients with spinal metastases. Investigating regional variations in surgical management could provide valuable insights to optimize care and refine surgical practices globally.</div></div><div><h3>Objective</h3><div>To investigate differences in patient populations, surgical management, and perioperative outcomes among patients who underwent surgery for spinal metastases in either Boston (United States) or Utrecht (Netherlands).</div></div><div><h3>Methods</h3><div>727 patients surgically treated for spinal metastases in Boston (n=539) and Utrecht (n=188) between 2018–2022 were included. Data on patient characteristics, surgical management, perioperative outcomes, and survival were collected. The Mann-Whitney <em>U</em> test was used for continuous data, and Fisher’s exact test for categorical data.</div></div><div><h3>Results</h3><div>In Boston, a higher percentage of patients had three or more spinal metastases (68% <em>vs</em> 59%; p=0.006) and brain metastases (16% <em>vs</em> 4.3%; p&lt;0.001) at the time of surgery compared with Utrecht. Vertebrectomy/corpectomy with stabilization was performed in 54% of patients in Boston versus none in Utrecht (p&lt;0.001), whereas percutaneous stabilization was performed in 1.3% of patients in Boston versus 39% in Utrecht (p&lt;0.001). In Utrecht, patients received postoperative radiotherapy more frequently (70% <em>vs</em> 54%; p&lt;0.001) and earlier (17 days [IQR:12–24] <em>vs</em> 29 days [IQR:23–39]; p&lt;0.001). Postoperative neurological outcome, complications, reoperation rates, and survival did not differ between the two cohorts (all p&gt;0.05).</div></div><div><h3>Conclusions</h3><div>Differences in patient populations and surgical management exist between tertiary hospitals on separate continents. Further research is needed to determine the optimal extent and timing of surgery to improve quality of life for patients with spinal metastases.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"52 ","pages":"Article 100676"},"PeriodicalIF":3.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}